再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

休市中 07-24 16:00:00 EDT

656.01

+4.10

+0.63%

盘后656.01

+0.000.00%

19:34 EDT

最高667.50	最低654.05	成交量70.84万
今开658.29	昨收651.91	日振幅2.06%
总市值693.53亿	流通市值677.68亿	总股本1.06亿
成交额4.67亿	换手率0.69%	流通股本1.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":656.01,"timestamp":1784923200000,"preClose":651.91,"halted":0,"volume":708392,"hourTrading":{"tag":"盘后","latestPrice":656.01,"preClose":656.01,"latestTime":"19:34 EDT","volume":27657,"amount":18143311.704,"timestamp":1784936049813,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0062892117010017075,"floatShares":103302739,"shares":105719806,"eps":41.06084,"marketStatus":"休市中","change":4.1,"latestTime":"07-24 16:00:00 EDT","open":658.29,"high":667.5,"low":654.05,"amount":467395738.15872,"amplitude":0.020632,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.06084,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":651.91,"dividendRate":0.005466,"preHourTrading":{"tag":"盘前","latestPrice":657.1132,"preClose":651.91,"latestTime":"09:28 EDT","volume":58,"amount":37845.7714,"timestamp":1784899739072,"change":5.2032,"changeRate":0.007981,"amplitude":0.090471},"postHourTrading":{"tag":"盘后","latestPrice":656.01,"preClose":656.01,"latestTime":"19:34 EDT","volume":27657,"amount":18143311.704,"timestamp":1784936049813,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9309787873428808,"impliedVol":0.3886,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"1116304977","title":"异动解读｜再生元制药盘中下跌3.28%，多家投行下调目标价叠加财报预警","url":"https://stock-news.laohu8.com/highlight/detail?id=1116304977","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116304977?lang=zh_cn&edition=full","pubTime":"2026-07-23 00:33","pubTimestamp":1784738021,"startTime":"0","endTime":"0","summary":"7月22日，再生元制药盘中下跌3.28%，报653.06美元/股，成交额1.23亿美元。消息面上，Cantor Fitzgerald于7月22日将再生元制药目标价从785美元下调至750美元，此前高盛也将目标价从968美元微调至965美元。近期HSBC更大幅将目标价从990美元削减至800美元。多家机构集中下调目标价，反映市场对公司前景的谨慎预期。此外，5月核心药物fianlimab联合疗法三期试验未达主要终点的阴影仍未完全消散，多重利空因素共振下股价承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125509855","title":"异动解读｜再生元制药盘前下跌3.2%，多家投行下调目标价叠加Q2业绩预警承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1125509855","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125509855?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:40","pubTimestamp":1784191203,"startTime":"0","endTime":"0","summary":"7月16日，再生元制药盘前下跌3.2%，报656.9美元/股。消息面上，近期多家投行密集下调公司目标价，叠加公司预告Q2每股收益将减少约1美元，市场情绪持续承压。此前公司提交SEC文件披露，预计Q2 GAAP及非GAAP每股摊薄收益将较预期减少约1美元，市场对7月30日即将发布的二季报表现存在担忧。此外，5月核心药物fianlimab三期试验未达主要终点的阴影仍未完全消散，多家机构此前已下调评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再生元制药盘前下跌3.2%，多家投行下调目标价叠加Q2业绩预警承压","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163828461","title":"异动解读｜再生元制药公司盘中上涨3.06%，入选FDA加速新生产设施审查计划提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1163828461","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163828461?lang=zh_cn&edition=full","pubTime":"2026-07-07 23:22","pubTimestamp":1783437731,"startTime":"0","endTime":"0","summary":"7月7日，再生元制药公司盘中上涨3.06%，报669.42美元/股，成交额1.18亿美元。消息面上，FDA近日启动加速新生产设施审查计划，再生元与礼来成为首批入选企业。该计划通过优化监管流程，缩短生产设施从建设到获批投产的时间，有助于提升公司产能布局的敏捷性。此外，公司核心药物Cemdisiran此前已获FDA优先审评资格，目标审评日期定于11月，管线推进节奏积极。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132494711","title":"再生元制药公司预计2026年第二季度GAAP及非GAAP每股摊薄收益将减少1美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1132494711","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132494711?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:03","pubTimestamp":1783335796,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，再生元制药公司（Regeneron Pharmaceuticals）预计，其2026年第二季度的美国通用会计准则（GAAP）及非美国通用会计准则（Non-GAAP）每股摊薄收益将出现下降，减少幅度约为1美元。这一预期反映了公司在特定时期内的财务表现可能面临的调整或挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IBBQ","LU0320765992.SGD","LU1974910355.USD","BK4585","LU2362541273.HKD","LU2089984988.USD","LU0058720904.USD","LU2362541513.USD","LU2468319806.SGD","IBB","LU2023250504.SGD","REGN","LU0109394709.USD","LU2106854487.HKD","LU0053666078.USD","LU0889565916.HKD","LU0823434740.USD","LU2362540622.SGD","LU0114720955.EUR","BBH","LU0823434583.USD","LU0882574055.USD","LU2237438978.USD","BK4139","LU0289739699.SGD","LU1917777945.USD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142675479","title":"礼来与再生元制药公司入选FDA首批加速新生产设施审查计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1142675479","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142675479?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:15","pubTimestamp":1783322114,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）近日启动了一项旨在加速新生产设施审查的倡议，而制药巨头礼来与再生元制药公司成为首批入选该计划的企业。此举旨在通过优化监管流程，缩短创新药物生产设施从建设到获批投产的时间，从而更快地将关键疗法推向市场。\n对于礼来和再生元而言，参与此计划意味着其未来新建或扩建的生产基地可能获得FDA更优先、更高效的审查。在当前全球生物制药竞争日益激烈的背景下，提升产能布局的敏捷性至关重要，尤其是在糖尿病、肥胖症、癌症及炎症性疾病等需求旺盛的治疗领域。这一监管合作模式有望成为行业加速发展的新催化剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","IE0009355771.USD","LU0097036916.USD","SGXZ99366536.SGD","BK4007","LU0345770993.USD","PJP","LU0823434583.USD","LU2087625088.SGD","SG9999001176.SGD","LU0006306889.USD","IE00B2B36J28.USD","LU0964807845.USD","LU0058720904.USD","LU2237443895.HKD","LU0158827948.USD","IE00BN29S564.USD","IE00B4R5TH58.HKD","IE0002141913.USD","IE0004445239.USD","IXJ","LU1064131342.USD","LU1868836914.USD","LU2471134523.USD","LU0683600562.USD","LU1623119135.USD","LU2491050154.USD","SG9999015986.USD","LU0456855351.SGD","LU2462157665.USD","SGXZ31699556.SGD","SGXZ51526630.SGD","LU2552382058.USD","LU0320765992.SGD","LU2023251221.USD","LU2456880835.USD","BBH","IE00BK4W5L77.USD","LU1868837136.USD","LU0256863811.USD","LU1983299246.USD","IE00BKPKM429.USD","LU0354030438.USD","LU0889565916.HKD","LU1023059063.AUD","IBBQ","IE00BJT1NW94.SGD","LU1127390331.HKD","LU2361044949.HKD","IE00BFSS7M15.SGD","LU2756315318.SGD","LU0256863902.USD","LU0122379950.USD","IE00BK4W5M84.HKD","IE00B4JS1V06.HKD","LU0158827781.USD","LU2237443465.HKD","LU2237443549.SGD","SG9999013999.USD","REGN","XLV","LU2112291526.USD","IE0005OL40V9.USD","ILDR","BK4533","LU0316494557.USD","IHE","LU1291159041.SGD","LU2213496289.HKD","LU2089284900.SGD","WDNA","CANC","LU0345770308.USD","GB00BDT5M118.USD","LU0823434740.USD","LU2491049909.HKD","LU2602419157.SGD","LU0323591593.USD","LU0672654240.SGD","LU2168564495.EUR","LU0203202063.USD","IE00BJJMRX11.SGD","IBB","LU1868836757.USD","IYH","LU0823416689.USD","MEDI","LU0708995401.HKD","LU1057294990.SGD","LU2106854487.HKD","LU0385154629.USD","LU1093756168.USD","LU0133085943.USD","LU0882574139.USD","LU2108987350.USD","LU2461242641.AUD","IE00BWXC8680.SGD","LLYZ","LU2089283258.USD","LU2324357040.USD","MEDX","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU2023250504.SGD","LU2746668974.SGD","IE00B1BXHZ80.USD","LU1280957306.USD","LU1551013425.SGD","LU2491050071.SGD","FHLC","BK4588","LU0266013472.USD","LU0061475181.USD","LU0210536198.USD","IE00B775H168.HKD","LU1061106388.HKD","LU2552382215.SGD","SG9999015945.SGD","SG9999015952.SGD","LU1868836591.USD","LU1720051108.HKD","LU2552382132.HKD","LU2265009873.SGD","LU2168563687.JPY","LU2028103732.USD","BK4516","LU2360106947.USD","LU1988902786.USD","LU1629891620.HKD","LU2750360997.AUD","LU0466842654.USD","LU2362541273.HKD","THNR","LU2264538146.SGD","LU2362540622.SGD","RXL","BK4139","LU2168564222.USD","LU1974910355.USD","LU1548497426.USD","LU1551013342.USD","LU0353189680.USD","LU0432979614.USD","LLII","LU0234572021.USD","IE00BFSS8Q28.SGD","LU0106261372.USD","LU0820562030.AUD","LU1323610961.USD","LU2361045086.USD","ELIL","LU1989771016.USD","SG9999014880.SGD","LU1069344957.HKD","LU2211815571.USD","LU0820561818.USD","LU2750360641.GBP","LLY","LU0198837287.USD","BK4599","LU0943347566.SGD","GDOC","LU2023250330.USD","LU2471134952.CNY","IE00BJLML261.HKD","IE00BKDWB100.SGD","LU1093756325.SGD","AGNG","LLYX","LU2237438978.USD","LU2746668461.USD","LU0471298777.SGD","BK4534","LU0417517546.SGD","SG9999017495.SGD","LU2237443978.SGD","LU0109391861.USD","LU1232071149.USD","PPH","LU0053666078.USD","LU0471298694.HKD","LU2063271972.USD","SG9999018865.SGD","LU0786609619.USD","LU0787776722.HKD","LU0225283273.USD","LU0640476718.USD","LU1917777945.USD","LU0820561909.HKD","LU2357305700.SGD","LU1712237335.SGD","IE00B7KXQ091.USD","LU2471134796.USD","LU1804176565.USD","FTXH","SG9999001176.USD","LU2468319806.SGD","LU1868837300.USD","LU0353189763.USD","SGXZ57979304.SGD","ELIS","LU0203201768.USD","LU2361044865.SGD","LU2089984988.USD","LU1035775433.USD","LU2236285917.USD","LU1366192091.USD","SG9999014898.SGD","IE0004445015.USD","LU2896262040.SGD","BK4581","LU2471134879.HKD","LU0238689110.USD","OZEM","LU0882574055.USD","LU2111349929.HKD","LU1145028129.USD","LU2756315664.SGD","BK4585","LU2417539215.USD","CURE","LU0354030511.USD","LU0079474960.USD","LU2237443382.USD","LU0094547139.USD","LU1267930730.SGD","VHT","LU0289739699.SGD","JDOC","LU2362541513.USD","LU1814569148.SGD","SG9999014906.USD","LU1720051017.SGD","LU0109394709.USD","LU0689472784.USD","LU2168564149.EUR","IE00B1XK9C88.USD","LU0320765059.SGD","SG9999014914.USD","LU2168564065.EUR","IE0001KFT4U8.USD","LU2237443622.USD","LU2271345857.HKD","HRTS","SG9999018857.SGD","SGXZ81514606.USD","IE00BJJMRY28.SGD","SG9999015978.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160625822","title":"异动解读｜再生元制药盘中上涨3.1%，入选FDA生产试点叠加创新药审评利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1160625822","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160625822?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:53","pubTimestamp":1783003990,"startTime":"0","endTime":"0","summary":"7月2日，再生元制药盘中上涨3.1%，报644.15美元/股，成交额8873.73万美元。消息面上，公司近期迎来多重利好催化。6月29日，美国FDA宣布再生元制药入选其新推出的PreCheck生产试点项目，该项目为企业提供更早期的监管沟通，提升美国本土药品生产的可预测性。此外，6月22日公司重症肌无力创新药Cemdisiran新药申请获FDA优先审评资格，目标审评日期定于11月，欧洲药品管理局亦同步受理。Cemdisiran若获批，有望成为全球首款治疗全身型重症肌无力的siRNA药物。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113725546","title":"美国FDA启动预审试点项目，安尼尔、Cellares、礼来、富士胶片等多家企业参与","url":"https://stock-news.laohu8.com/highlight/detail?id=1113725546","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113725546?lang=zh_cn&edition=full","pubTime":"2026-06-30 04:30","pubTimestamp":1782765004,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局的“预审”试点项目迎来了一批重量级参与者。该计划旨在优化新药和疗法的审查流程，而此次加入的安尼尔制药、Cellares、礼来、富士胶片、Kriya、协和麒麟以及再生元制药等公司，无疑为项目注入了强大的行业动力。这一举措标志着FDA在推动监管科学创新、加速潜在疗法上市方面迈出了新的一步。通过让领先的制药与生物技术公司提前介入，FDA期望能更高效地识别和解决开发过程中的关键问题，从而最终惠及等待新疗法的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2750360641.GBP","LU0823434583.USD","LU0114720955.EUR","LU1057294990.SGD","LU2237443622.USD","SGXZ99366536.SGD","LU1069344957.HKD","LU0058720904.USD","IE00B1XK9C88.USD","LU2602419157.SGD","LU1804176565.USD","LU1267930730.SGD","LU2357305700.SGD","LU2108987350.USD","LU1145028129.USD","LU1868837136.USD","IE0004445239.USD","LU0820562030.AUD","LU2168564222.USD","LU2087625088.SGD","LU0320765059.SGD","ELIS","LU2023250330.USD","BK4139","IE00BJJMRY28.SGD","LU1868836591.USD","LU2360106947.USD","LU1023059063.AUD","SG9999015945.SGD","LU2750360997.AUD","SG9999017495.SGD","LU2236285917.USD","LU0006306889.USD","LU1035775433.USD","LU1061106388.HKD","LU2237443382.USD","LU2265009873.SGD","LU0061475181.USD","LU1323610961.USD","LU2361044949.HKD","LU0106261372.USD","LU0109391861.USD","LU0787776722.HKD","LU1988902786.USD","BK4585","LU0234572021.USD","LU0158827948.USD","LU1720051017.SGD","SGXZ57979304.SGD","LU2023251221.USD","LU0097036916.USD","LU2089284900.SGD","LU2106854487.HKD","SG9999001176.SGD","LU2361044865.SGD","LU0203202063.USD","IE00BFSS8Q28.SGD","LU2456880835.USD","LU2471134796.USD","LU2491049909.HKD","LU2471134879.HKD","LU2063271972.USD","LU2552382132.HKD","LU0640476718.USD","BK4516","LU1989771016.USD","SG9999018865.SGD","LU1814569148.SGD","LU0122379950.USD","LU0266013472.USD","LU0882574055.USD","LU2271345857.HKD","BK4534","BK4007","SG9999013999.USD","LU0133085943.USD","SG9999015986.USD","LU1280957306.USD","SGXZ51526630.SGD","LU0109394709.USD","LU0289739699.SGD","LU0094547139.USD","LU0417517546.SGD","LU2237443978.SGD","BK4599","LU0079474960.USD","LU0672654240.SGD","LU0471298777.SGD","LU1623119135.USD","LU2112291526.USD","LU2362540622.SGD","SG9999014898.SGD","LU2471134523.USD","LU2471134952.CNY","LU1232071149.USD","IE00BKDWB100.SGD","IE00BFSS7M15.SGD","LLII","LU0354030511.USD","LU0385154629.USD","LU2491050071.SGD","IE0004445015.USD","LU2468319806.SGD","LU1127390331.HKD","LU0210536198.USD","LU0683600562.USD","LU0689472784.USD","LU2756315318.SGD","LU1093756168.USD","BK4170","LU2168563687.JPY","LU0256863811.USD","LU0456855351.SGD","LU2362541513.USD","LU0708995401.HKD","LU2168564495.EUR","SG9999014914.USD","LU0823416689.USD","IE00B1BXHZ80.USD","LU2028103732.USD","LU2023250504.SGD","LU2237438978.USD","IE00BJJMRZ35.SGD","LU2746668461.USD","LU2896262040.SGD","AMRX","SG9999018857.SGD","LU0320765992.SGD","LU1629891620.HKD","LU2417539215.USD","IE00BK4W5L77.USD","LU0432979614.USD","KYKOF","LU1064131342.USD","IE0009355771.USD","LU2168564065.EUR","IE00BFTCPJ56.SGD","LU0323591593.USD","SG9999014906.USD","SGXZ81514606.USD","IE00BWXC8680.SGD","SG9999015952.SGD","IE00BN29S564.USD","SG9999001176.USD","IE0005OL40V9.USD","LU1917777945.USD","LU2264538146.SGD","LU0786609619.USD","SG9999015978.USD","LU2461242641.AUD","IE0001KFT4U8.USD","SG9999014880.SGD","IE00B4R5TH58.HKD","LU1983299246.USD","ELIL","BK4588","LU1093756325.SGD","LU1868836914.USD","LLYZ","LU0256863902.USD","LU0353189763.USD","LU0466842654.USD","LU0823434740.USD","LU0943347566.SGD","LU1366192091.USD","LU0316494557.USD","LU1291159041.SGD","LU1551013425.SGD","LU1868836757.USD","LU1868837300.USD","SGXZ31699556.SGD","LU2237443465.HKD","IE00BK4W5M84.HKD","LU0964807845.USD","BK4533","LU2213496289.HKD","LU0238689110.USD","LU2756315664.SGD","IE00B4JS1V06.HKD","LU2552382058.USD","LU0053666078.USD","LU0225283273.USD","LU0820561818.USD","LU2089984988.USD","LU2111349929.HKD","LU0354030438.USD","LU0158827781.USD","REGN","IE00BJT1NW94.SGD","LU0882574139.USD","LU1720051108.HKD","IE00B775H168.HKD","LU2324357040.USD","LU1974910355.USD","FUJIF","LU2362541273.HKD","IE00B2B36J28.USD","LU0471298694.HKD","LU2237443895.HKD","BK4581","LU2089283258.USD","LU0889565916.HKD","GB00BDT5M118.USD","LU2491050154.USD","IE0002141913.USD","LU2211815571.USD","LU0203201768.USD","LU1551013342.USD","IE00BJLML261.HKD","LLYX","IE00BJJMRX11.SGD","LU2552382215.SGD","LLY","IE00BKPKM429.USD","LU2361045086.USD","LU2462157665.USD","IE00B7KXQ091.USD","LU0198837287.USD","LU2237443549.SGD","LU0096364046.USD","LU2168564149.EUR","LU1712237335.SGD","LU1548497426.USD","LU0353189680.USD","LU0820561909.HKD","LU2746668974.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139730577","title":"礼来、再生元制药等首批入选FDA加速新生产设施审批计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1139730577","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139730577?lang=zh_cn&edition=full","pubTime":"2026-06-30 02:54","pubTimestamp":1782759286,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局近日启动了一项旨在加速新生产设施审批流程的倡议，而礼来与再生元制药公司等企业已获选成为该计划的首批参与者。通过简化流程、加强前期沟通与协作，FDA期望能显著缩短药物生产设施从建设到投入运营所需的时间。业界观察人士认为，这一倡议反映了FDA在面对生物医药产业快速发展和供应链韧性需求时，正积极采取更主动、协作的监管方式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","IE00BFSS8Q28.SGD","LU1623119135.USD","LU2746668461.USD","LU2087625088.SGD","GB00BDT5M118.USD","LU2552382215.SGD","LU1804176565.USD","LU0672654240.SGD","ELIS","LU1291159041.SGD","LU2168563687.JPY","LU2168564495.EUR","LU0316494557.USD","LU1145028129.USD","LU0882574055.USD","BK4516","SG9999015986.USD","LU1323610961.USD","LU1868837136.USD","LU2362541273.HKD","IE0005OL40V9.USD","LLYZ","LU1814569148.SGD","BK4007","LU2602419157.SGD","SG9999015945.SGD","LU1023059063.AUD","IE00BN29S564.USD","LU2265009873.SGD","LU2417539215.USD","LU2237443622.USD","LU1868837300.USD","LU2491050154.USD","SG9999018865.SGD","LU0456855351.SGD","LLY","SGXZ99366536.SGD","LU0289739699.SGD","LU1093756168.USD","LU0114720955.EUR","IE00BFTCPJ56.SGD","LU2360106947.USD","LU2106854487.HKD","LU1548497426.USD","LU0353189763.USD","LU2471134952.CNY","LU0203201768.USD","LU2237443978.SGD","LU2471134796.USD","LU2023251221.USD","LU2361044949.HKD","BK4599","IE00B4JS1V06.HKD","LU2361044865.SGD","LU1127390331.HKD","IE00B1XK9C88.USD","LU2237443465.HKD","IE00BJLML261.HKD","LU2362541513.USD","LU1868836591.USD","IE00BWXC8680.SGD","IE0004445239.USD","LU0198837287.USD","LU1629891620.HKD","LU2491049909.HKD","LU1061106388.HKD","LU1064131342.USD","LU2756315664.SGD","LU0640476718.USD","IE0001KFT4U8.USD","LU2552382132.HKD","LU0109391861.USD","SGXZ57979304.SGD","LU0943347566.SGD","LLYX","LU0823416689.USD","LU1974910355.USD","LU0323591593.USD","LU2361045086.USD","LU0053666078.USD","LU1232071149.USD","LU0708995401.HKD","LLII","LU0266013472.USD","LU0256863811.USD","LU0320765059.SGD","LU0683600562.USD","LU2213496289.HKD","LU0354030511.USD","LU0820561909.HKD","LU1093756325.SGD","LU2357305700.SGD","LU0079474960.USD","LU2237438978.USD","SG9999001176.SGD","LU2264538146.SGD","IE00BKDWB100.SGD","LU2111349929.HKD","IE00BKPKM429.USD","BK4533","LU0122379950.USD","LU0058720904.USD","LU0006306889.USD","LU0466842654.USD","LU2756315318.SGD","LU1983299246.USD","SG9999014906.USD","IE0004445015.USD","SGXZ51526630.SGD","LU0203202063.USD","LU1868836757.USD","LU0820561818.USD","LU2023250330.USD","BK4588","LU2168564149.EUR","IE00BJJMRZ35.SGD","LU1267930730.SGD","LU1989771016.USD","SGXZ31699556.SGD","LU1551013425.SGD","LU2089283258.USD","LU0820562030.AUD","LU0106261372.USD","LU2237443382.USD","LU2462157665.USD","LU2750360641.GBP","SG9999018857.SGD","IE00BK4W5M84.HKD","LU1868836914.USD","IE00B775H168.HKD","LU2362540622.SGD","LU2491050071.SGD","IE00B7KXQ091.USD","LU2750360997.AUD","IE00BJT1NW94.SGD","LU2063271972.USD","IE00BJJMRY28.SGD","LU2089984988.USD","SG9999014880.SGD","IE00B1BXHZ80.USD","LU0320765992.SGD","LU1280957306.USD","LU0889565916.HKD","SGXZ81514606.USD","REGN","LU0133085943.USD","LU2023250504.SGD","SG9999015978.USD","SG9999001176.USD","LU0234572021.USD","LU0787776722.HKD","LU0786609619.USD","LU2108987350.USD","SG9999014898.SGD","LU2468319806.SGD","IE0002141913.USD","IE0009355771.USD","LU0354030438.USD","LU2211815571.USD","LU2461242641.AUD","LU0256863902.USD","LU0158827781.USD","LU2089284900.SGD","SG9999014914.USD","LU1720051108.HKD","LU0094547139.USD","LU2168564222.USD","LU1988902786.USD","LU2028103732.USD","ELIL","LU0238689110.USD","LU1057294990.SGD","LU1366192091.USD","IE00BK4W5L77.USD","LU2471134879.HKD","LU0353189680.USD","SG9999017495.SGD","LU1720051017.SGD","LU0097036916.USD","LU0471298777.SGD","LU2168564065.EUR","LU1069344957.HKD","LU0061475181.USD","BK4585","LU0823434740.USD","IE00B4R5TH58.HKD","LU2456880835.USD","LU0210536198.USD","IE00B2B36J28.USD","LU0471298694.HKD","LU0882574139.USD","LU2896262040.SGD","LU0689472784.USD","LU2237443549.SGD","IE00BJJMRX11.SGD","LU2552382058.USD","LU2236285917.USD","LU0096364046.USD","LU2271345857.HKD","IE00BFSS7M15.SGD","LU0385154629.USD","LU2471134523.USD","BK4581","LU2746668974.SGD","LU1917777945.USD","LU2112291526.USD","LU0225283273.USD","LU0432979614.USD","BK4534","LU2237443895.HKD","LU1551013342.USD","LU0417517546.SGD","LU1712237335.SGD","SG9999015952.SGD","LU0964807845.USD","LU1035775433.USD","SG9999013999.USD","LU0109394709.USD","LU0158827948.USD","LU2324357040.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647587301","title":"市场消息：礼来、再生元等首批企业入选美国食品药品监督管理局全新审批提速项目，该项目旨在加快新生产厂房的审核流程。","url":"https://stock-news.laohu8.com/highlight/detail?id=2647587301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647587301?lang=zh_cn&edition=full","pubTime":"2026-06-30 02:53","pubTimestamp":1782759209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0823434583.USD","IE00BFSS8Q28.SGD","LU1623119135.USD","LU2746668461.USD","LU2087625088.SGD","GB00BDT5M118.USD","LU2552382215.SGD","LU1804176565.USD","LU0672654240.SGD","ELIS","LU1291159041.SGD","LU2168563687.JPY","LU2168564495.EUR","LU0316494557.USD","LU1145028129.USD","LU0882574055.USD","BK4516","SG9999015986.USD","LU1323610961.USD","LU1868837136.USD","LU2362541273.HKD","IE0005OL40V9.USD","LLYZ","LU1814569148.SGD","BK4007","LU2602419157.SGD","SG9999015945.SGD","LU1023059063.AUD","IE00BN29S564.USD","LU2265009873.SGD","LU2417539215.USD","LU2237443622.USD","LU1868837300.USD","LU2491050154.USD","SG9999018865.SGD","LU0456855351.SGD","LLY","SGXZ99366536.SGD","LU0289739699.SGD","LU1093756168.USD","LU0114720955.EUR","IE00BFTCPJ56.SGD","LU2360106947.USD","LU2106854487.HKD","LU1548497426.USD","LU0353189763.USD","LU2471134952.CNY","LU0203201768.USD","LU2237443978.SGD","LU2471134796.USD","LU2023251221.USD","LU2361044949.HKD","BK4599","IE00B4JS1V06.HKD","LU2361044865.SGD","LU1127390331.HKD","IE00B1XK9C88.USD","LU2237443465.HKD","IE00BJLML261.HKD","LU2362541513.USD","LU1868836591.USD","IE00BWXC8680.SGD","IE0004445239.USD","LU0198837287.USD","LU1629891620.HKD","LU2491049909.HKD","LU1061106388.HKD","LU1064131342.USD","LU2756315664.SGD","LU0640476718.USD","IE0001KFT4U8.USD","LU2552382132.HKD","LU0109391861.USD","SGXZ57979304.SGD","LU0943347566.SGD","LLYX","LU0823416689.USD","LU1974910355.USD","LU0323591593.USD","LU2361045086.USD","LU0053666078.USD","LU1232071149.USD","LU0708995401.HKD","LLII","LU0266013472.USD","LU0256863811.USD","LU0320765059.SGD","LU0683600562.USD","LU2213496289.HKD","LU0354030511.USD","LU0820561909.HKD","LU1093756325.SGD","LU2357305700.SGD","LU0079474960.USD","LU2237438978.USD","SG9999001176.SGD","LU2264538146.SGD","IE00BKDWB100.SGD","LU2111349929.HKD","IE00BKPKM429.USD","BK4533","LU0122379950.USD","LU0058720904.USD","LU0006306889.USD","LU0466842654.USD","LU2756315318.SGD","LU1983299246.USD","SG9999014906.USD","IE0004445015.USD","SGXZ51526630.SGD","LU0203202063.USD","LU1868836757.USD","LU0820561818.USD","LU2023250330.USD","BK4588","LU2168564149.EUR","IE00BJJMRZ35.SGD","LU1267930730.SGD","LU1989771016.USD","SGXZ31699556.SGD","LU1551013425.SGD","LU2089283258.USD","LU0820562030.AUD","LU0106261372.USD","LU2237443382.USD","LU2462157665.USD","LU2750360641.GBP","SG9999018857.SGD","IE00BK4W5M84.HKD","LU1868836914.USD","IE00B775H168.HKD","LU2362540622.SGD","LU2491050071.SGD","IE00B7KXQ091.USD","LU2750360997.AUD","IE00BJT1NW94.SGD","LU2063271972.USD","IE00BJJMRY28.SGD","LU2089984988.USD","SG9999014880.SGD","IE00B1BXHZ80.USD","LU0320765992.SGD","LU1280957306.USD","LU0889565916.HKD","SGXZ81514606.USD","REGN","LU0133085943.USD","LU2023250504.SGD","SG9999015978.USD","SG9999001176.USD","LU0234572021.USD","LU0787776722.HKD","LU0786609619.USD","LU2108987350.USD","SG9999014898.SGD","LU2468319806.SGD","IE0002141913.USD","IE0009355771.USD","LU0354030438.USD","LU2211815571.USD","LU2461242641.AUD","LU0256863902.USD","LU0158827781.USD","LU2089284900.SGD","SG9999014914.USD","LU1720051108.HKD","LU0094547139.USD","LU2168564222.USD","LU1988902786.USD","LU2028103732.USD","ELIL","LU0238689110.USD","LU1057294990.SGD","LU1366192091.USD","IE00BK4W5L77.USD","LU2471134879.HKD","LU0353189680.USD","SG9999017495.SGD","LU1720051017.SGD","LU0097036916.USD","LU0471298777.SGD","LU2168564065.EUR","LU1069344957.HKD","LU0061475181.USD","BK4585","LU0823434740.USD","IE00B4R5TH58.HKD","LU2456880835.USD","LU0210536198.USD","IE00B2B36J28.USD","LU0471298694.HKD","LU0882574139.USD","LU2896262040.SGD","LU0689472784.USD","LU2237443549.SGD","IE00BJJMRX11.SGD","LU2552382058.USD","LU2236285917.USD","LU0096364046.USD","LU2271345857.HKD","IE00BFSS7M15.SGD","LU0385154629.USD","LU2471134523.USD","BK4581","LU2746668974.SGD","LU1917777945.USD","LU2112291526.USD","LU0225283273.USD","LU0432979614.USD","BK4534","LU2237443895.HKD","LU1551013342.USD","LU0417517546.SGD","LU1712237335.SGD","SG9999015952.SGD","LU0964807845.USD","LU1035775433.USD","SG9999013999.USD","LU0109394709.USD","LU0158827948.USD","LU2324357040.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645222700","title":"再生元制药(REGN)重症肌无力创新药获美欧监管受理  有望成全球首款治疗该症的siRNA药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2645222700","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645222700?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:32","pubTimestamp":1782131526,"startTime":"0","endTime":"0","summary":"该药用于治疗抗乙酰胆腺受体抗体阳性的成人全身型重症肌无力患者。作为一款针对补体系统C5靶点的小干扰RNA疗法，Cemdisiran若能获批，有望成为全球首款用于治疗gMG的siRNA药物。目前，Cemdisiran仍处于临床研究阶段，其安全性和疗效尚未获得任何国家监管机构的最终批准。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301751","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","BK1161","LU0823416689.USD","LU0058720904.USD","BK4139","LU0053666078.USD","01477","LU0320765992.SGD","LU0823434740.USD","LU2089984988.USD","LU2023250504.SGD","BK1191","LU2237438978.USD","BK4585","06978","159992","BK4588","LU0109394709.USD","LU0114720955.EUR","LU0882574055.USD","LU1917777945.USD","LU0289739699.SGD","LU0889565916.HKD","LU2468319806.SGD","LU1974910355.USD","LU2362541273.HKD","REGN","LU2106854487.HKD","LU0823434583.USD","BK1574","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131217305","title":"再生元制药Cemdisiran新药申请获FDA优先审评资格，目标审评日期定于2026年11月","url":"https://stock-news.laohu8.com/highlight/detail?id=1131217305","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131217305?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:03","pubTimestamp":1782126209,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已接受对再生元制药公司（Regeneron Pharmaceuticals）旗下药物Cemdisiran的新药申请（NDA）进行审评，并授予其优先审评资格。该申请的目标审评日期定于2026年11月。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0889565916.HKD","LU2089984988.USD","BK4588","LU2468319806.SGD","LU2023250504.SGD","LU0114720955.EUR","LU0823434740.USD","LU1974910355.USD","LU0289739699.SGD","BK4139","LU0882574055.USD","LU2362541273.HKD","LU0109394709.USD","LU0058720904.USD","LU0053666078.USD","LU2106854487.HKD","LU2362540622.SGD","LU1917777945.USD","LU0823434583.USD","LU2362541513.USD","LU0823416689.USD","LU2237438978.USD","LU0320765992.SGD","REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118743106","title":"再生元制药公司旗下药物Cemdisira的欧盟审批决定预计于2027年下半年揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1118743106","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118743106?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:02","pubTimestamp":1782126136,"startTime":"0","endTime":"0","summary":"再生元制药公司（Regeneron Pharmaceuticals）研发的药物Cemdisira，其欧洲市场准入的关键性裁决——欧盟委员会的审批决定，预计将在2027年下半年作出。这一时间点标志着该药物在欧洲监管流程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU0823434740.USD","LU2237438978.USD","LU1974910355.USD","BK4585","LU0109394709.USD","LU0889565916.HKD","LU2089984988.USD","LU2468319806.SGD","LU0882574055.USD","LU0289739699.SGD","BK4139","BK4588","LU2362540622.SGD","LU2106854487.HKD","LU2362541513.USD","LU0053666078.USD","LU0058720904.USD","LU0320765992.SGD","LU0823434583.USD","LU1917777945.USD","LU0114720955.EUR","LU0823416689.USD","LU2023250504.SGD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104752887","title":"异动解读｜再生元制药公司盘中下跌3.07%，三期临床失败叠加Eylea生物类似药申请重压","url":"https://stock-news.laohu8.com/highlight/detail?id=1104752887","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104752887?lang=zh_cn&edition=full","pubTime":"2026-06-09 00:29","pubTimestamp":1780936189,"startTime":"0","endTime":"0","summary":"6月8日，再生元制药公司盘中下跌3.07%，报615.91美元/股，成交额1.57亿美元。消息面上，多重利空共振施压股价。此外，冰岛生物制药公司Alvotech联合Teva再次向FDA提交针对再生元核心产品Eylea的生物类似药上市申请，进一步加剧市场对其眼科业务收入遭受侵蚀的担忧。同日生物科技板块整体承压，艾伯维跌2.35%、吉利德跌1.41%、安进跌1.18%，行业情绪偏弱加大下行压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128409346","title":"Parabilis Medicines拟将约1.5亿美元IPO收益用于继续推进Zolucatetide治疗硬纤维瘤的临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1128409346","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128409346?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:21","pubTimestamp":1780568476,"startTime":"0","endTime":"0","summary":"Parabilis Medicines公司计划，将首次公开募股所筹资金中的约1.5亿美元，用于持续推动其候选药物Zolucatetide在硬纤维瘤领域的临床开发进程。此举旨在加速该疗法的研发，以应对这一临床需求未满足的疾病领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0320765992.SGD","LU0889565916.HKD","LU2468319806.SGD","LU0109394709.USD","BK4585","LU1974910355.USD","LU2106854487.HKD","BK4139","LU0823416689.USD","LU0823434740.USD","BK4588","LU1917777945.USD","LU2089984988.USD","LU2237438978.USD","LU2362541273.HKD","LU2362541513.USD","LU0823434583.USD","LU2023250504.SGD","LU0058720904.USD","LU0114720955.EUR","REGN","LU0053666078.USD","LU0289739699.SGD","LU2362540622.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111077391","title":"Parabilis Medicines宣布与再生元制药达成协议，后者将斥资约7500万美元在同步私募中认购其普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1111077391","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111077391?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:20","pubTimestamp":1780568423,"startTime":"0","endTime":"0","summary":"再生元制药公司已同意在一项同步进行的私募融资中，以约7500万美元的价格购入Parabilis Medicines Inc的普通股。此项交易标志着两家生物技术公司在资本层面的重要合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","REGN","LU0053666078.USD","LU2362541273.HKD","LU0289739699.SGD","LU1917777945.USD","BK4139","LU0114720955.EUR","LU0320765992.SGD","LU2468319806.SGD","LU1974910355.USD","LU2362540622.SGD","LU2089984988.USD","LU0823434740.USD","LU0882574055.USD","LU2106854487.HKD","LU0109394709.USD","LU0889565916.HKD","LU0058720904.USD","LU0823416689.USD","LU2362541513.USD","BK4588","LU0823434583.USD","BK4585","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157154735","title":"异动解读｜再生元制药公司盘中上涨3.07%，埃博拉抗体获世卫组织推荐叠加合作扩展提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1157154735","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157154735?lang=zh_cn&edition=full","pubTime":"2026-06-04 00:35","pubTimestamp":1780504537,"startTime":"0","endTime":"0","summary":"6月3日，再生元制药公司盘中上涨3.07%，报621.42美元/股，成交额2.1亿美元。消息面上，多重利好共振推动股价走强。一方面，世界卫生组织推荐再生元研发的单克隆抗体Maftivimab用于应对当前本迪布焦型埃博拉病毒疫情，体外实验数据显示该药物对包括邦迪布焦病毒在内的多种埃博拉病毒株具有广泛抗病毒活性，为公司管线增添公共卫生应急价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133955723","title":"CytomX与再生元制药公司达成新协议：再生元获得6个额外靶点的选择权，潜在里程碑总额高达约40亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133955723","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133955723?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:05","pubTimestamp":1780488342,"startTime":"0","endTime":"0","summary":"生物技术公司CytomX与再生元制药公司之间的合作迎来了重大扩展。根据最新协议，再生元已获得针对6个额外靶点的选择权，此举有望将双方的合作范围进一步拓宽。协议条款显示，再生元制药公司为获得这些新靶点的选择权，已向CytomX支付了一笔预付款。若将现有合作中的潜在付款与此次新增的里程碑款项相结合，CytomX从这项合作中可能获得的总里程碑付款最高可达约40亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","LU2362541513.USD","REGN","LU1917777945.USD","LU2106854487.HKD","LU0053666078.USD","LU0882574055.USD","LU0114720955.EUR","BK4585","LU2362541273.HKD","LU0320765992.SGD","LU0823434740.USD","LU2089984988.USD","CTMX","LU2237438978.USD","LU0889565916.HKD","LU2362540622.SGD","LU1974910355.USD","LU0823434583.USD","LU2023250504.SGD","LU0823416689.USD","LU0058720904.USD","LU2468319806.SGD","LU0289739699.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194253037","title":"再生元制药公司：Maftivimab在体外对包括邦迪布焦在内的多种埃博拉病毒株展现广泛活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1194253037","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194253037?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:01","pubTimestamp":1779998475,"startTime":"0","endTime":"0","summary":"再生元制药公司公布的研究数据显示，其单克隆抗体疗法Maftivimab在体外实验中，对包括邦迪布焦病毒在内的多种埃博拉病毒物种均表现出广泛的抗病毒活性。这一发现为该疗法的潜在应用范围提供了新的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU2237438978.USD","LU0058720904.USD","LU2362541273.HKD","LU0823434583.USD","LU2089984988.USD","LU0882574055.USD","LU1917777945.USD","LU0114720955.EUR","BK4588","LU0289739699.SGD","LU2362540622.SGD","LU2362541513.USD","BK4139","REGN","LU0109394709.USD","LU0053666078.USD","LU2106854487.HKD","LU0823416689.USD","LU2468319806.SGD","BK4585","LU1974910355.USD","LU0823434740.USD","LU2023250504.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148240042","title":"再生元制药：Maftivimab获推荐作为单药疗法在当前疫情中展开研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1148240042","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148240042?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:01","pubTimestamp":1779998471,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其单克隆抗体药物Maftivimab已获建议，在当前爆发的疫情中作为单药疗法进行深入研究。这一推荐基于对该药物潜在疗效的初步评估，旨在探索其在独立使用时的安全性与有效性，为应对公共卫生挑战提供新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","REGN","LU1917777945.USD","LU2106854487.HKD","LU2362540622.SGD","LU2362541273.HKD","LU2468319806.SGD","LU2237438978.USD","LU0114720955.EUR","BK4139","BK4588","LU2023250504.SGD","LU1974910355.USD","LU0058720904.USD","LU2362541513.USD","LU0109394709.USD","LU0823416689.USD","LU0823434583.USD","LU2089984988.USD","LU0289739699.SGD","LU0882574055.USD","BK4585","LU0823434740.USD","LU0053666078.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148009972","title":"再生元埃博拉抗体获世卫组织推荐，用于应对当前本迪布焦型埃博拉病毒疫情","url":"https://stock-news.laohu8.com/highlight/detail?id=1148009972","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148009972?lang=zh_cn&edition=full","pubTime":"2026-05-29 04:00","pubTimestamp":1779998412,"startTime":"0","endTime":"0","summary":"世界卫生组织已推荐将再生元制药公司研发的埃博拉抗体，用于应对当前爆发的本迪布焦型埃博拉病毒疫情，并建议在调查性框架下使用。这一建议旨在为应对此次疫情提供一种潜在的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU0320765992.SGD","LU1917777945.USD","LU2362541273.HKD","LU0053666078.USD","LU0889565916.HKD","LU1974910355.USD","BK4585","LU0882574055.USD","LU2362541513.USD","LU0114720955.EUR","LU0109394709.USD","LU0823416689.USD","LU2237438978.USD","REGN","LU2362540622.SGD","LU0823434583.USD","LU2468319806.SGD","LU2089984988.USD","LU0289739699.SGD","BK4139","LU0058720904.USD","BK4588","LU2106854487.HKD","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0306},{"period":"1month","weight":0.0523},{"period":"3month","weight":-0.1271},{"period":"6month","weight":-0.1294},{"period":"1year","weight":0.1618},{"period":"ytd","weight":-0.1501}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.052257},{"month":6,"riseRate":0.444444,"avgChangeRate":0.006953},{"month":7,"riseRate":0.666667,"avgChangeRate":0.05263},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}